Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics (NQ: RVNC )

6.845 -0.095 (-1.37%)
Streaming Delayed Price Updated: 9:47 AM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Revance Therapeutics

< Previous 1 2 3 4 5 6 7 8 Next >
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
REVANCE THERAPEUTICS SHAREHOLDER NOTICE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
REVANCE THERAPEUTICS SHAREHOLDER ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Lost Money in Revance Therapeutics, Inc.?
From Gibbs Law Group
Via Business Wire
REVANCE THERAPEUTICS INVESTOR ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Revance Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines
From Revance Therapeutics, Inc.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
RVNC BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation – RVNC
From Rosen Law Firm
Via Business Wire
Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces the Launch of OPUL™, the First-of-its-Kind Relational Commerce Platform for Aesthetic Practices
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021
From Revance Therapeutics, Inc.
Via Business Wire
Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in the Wells Fargo Securities Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in Upcoming Virtual Healthcare Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA’s 24-Week Long Duration Profile Across Multiple Female Age Cohorts
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Present Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Fillers at American Academy of Dermatology VMX Meeting 2021
From Revance Therapeutics
Via Business Wire
Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.